

Ufenau Continuation 3 successfully exits Altano International

**Dear Investors,
Partners and Friends of Ufenau Capital Partners,**

Pfäffikon (CH), 24 September 2026

We are pleased to announce that Ufenau Continuation 3, SLP, a fund exclusively advised by Ufenau Capital Partners GmbH (“Ufenau”), has agreed to sell its stake in Altano International GmbH (“Altano”, the “Group” or the “Company”) to funds advised by Bridgepoint.

Ufenau first invested in Altano in 2017 via Ufenau V German Asset Light SLP. Having successfully grown Altano from a single-site veterinary care clinic with sub-EUR 10m sales at entry in 2017, Altano was rolled over into Ufenau Continuation 3 in 2023, and has since gone on to become the leading global equine veterinary group, bringing together 110 equine clinics and ambulatory practices and a network of almost 1,000 veterinarians across Europe, North America and Oceania. Today, Altano provides a comprehensive range of premium services, including routine and emergency veterinary care, advanced imaging, surgery, sports medicine and breeding services with the highest level of care, whilst generating more than EUR 350m of sales.

Through its partnership with management, Ufenau supported Altano’s international expansion and the development of an integrated network of leading equine veterinary practices, creating a differentiated platform with a strong market position and significant capabilities across geographies and clinical disciplines.

Dr. Victor Baltus, Founder and CEO of Altano, commented: “Altano was founded with the conviction that collaboration among veterinarians is key to advancing equine medicine. Over the past years, together with Ufenau, we have built a unique international network that combines clinical expertise, education, knowledge sharing and research to advance standards of care. I would like to thank the entire Ufenau team for their continuous support and partnership throughout this journey. Together, we have put in place a strong and lasting foundation for the next chapter of Altano’s growth and once again have a partner who understands what we have built so far, shares our vision and has the expertise to support us in continuing to take Altano to the next level.”

Dieter Scheiff, Senior Partner of Ufenau, commented: “We are proud of what the team has achieved together with Dr. Baltus over the last 9 years. From relatively humble beginnings and through the establishment of our continuation vehicle to further scale the business, Altano is today the world’s leading and largest equine veterinary platform. We are confident they have found the right partner to support continued future growth and wish Dr. Baltus and the entire Altano team every success for the future.”

The transaction is subject to customary closing conditions and is expected to close by the end of 2026.

Ufenau was advised by Jefferies (M&A), McKinsey (Commercial), PwC (Financial and Tax), and Görg (Lead Counsel).

Your Ufenau Team

About Ufenau Capital Partners

Ufenau Capital Partners is a privately owned Swiss Investor Group headquartered on lake Zurich. Ufenau advises private and institutional investors on private equity investments and focuses on service companies in German-speaking Europe, Iberia, Poland, the Benelux region, the UK, and the USA. The firm invests primarily in the Business Services, IT Services, Education & Lifestyle, Healthcare Services, and Financial Services sectors. Since 2011, Ufenau has invested in c.500 service companies globally. Through a renowned group of experienced Industry Partners (owners, CEOs, CFOs), Ufenau has an active, value-adding investment approach and works at eye level with entrepreneurs and managers. Ufenau advises capital of more than EUR 5.0 billion.